Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
In an attempt to improve the therapeutic index for initial therapy of metastatic NSCLC, the
combination of bevacizumab and erlotinib is being proposed as first-line treatment in place
of conventional chemotherapy. This trial is intended to provide pilot data for a future
randomized trial of this combination of targeted agents versus conventional chemotherapy for
advanced NSCLC.